Comparative Pharmacology
Head-to-head clinical analysis: BACTOCILL versus BICILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACTOCILL versus BICILLIN.
BACTOCILL vs BICILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BACTOCILL (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibitors. Active against Staphylococcus aureus and other gram-positive bacteria.
Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition, leading to cell lysis.
250-500 mg orally every 6 hours or 1-2 g intravenously every 4-6 hours
Benzathine penicillin G 1.2 million units intramuscularly once for early syphilis; 2.4 million units intramuscularly weekly for 3 weeks for late latent syphilis.
None Documented
None Documented
0.5-0.8 hours; prolonged to 2-4 hours in severe renal impairment
Terminal elimination half-life: 0.5–1 hour (prolonged in renal impairment); clinical context: requires probenecid for extended action
Renal: 60-70% unchanged; biliary: 20-30% as active metabolite; fecal: 5-10%
Primarily renal (60–70% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic